Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 271 results for "lupin"

Ten stocks to keep an eye on August 6
Money Control

Here are top 10 stocks to focus on August 28

Here are top 10 stocks to focus on August 28 - HDFC, Lupin, DLF, MCX, Adani Power, UPL, Kalindee Rail, Nitesh Estates, Piramal Enterprises and TV Today. Money Control, 2 hours ago
Ten stocks to keep an eye on August 6 Money Control, 3 weeks ago

82 images for lupin

Farm Weekly, 1 day ago, 2 days ago, 4 hours ago
Newswise, 2 days ago
Methow Valley News, 4 days ago
EMax Health, 1 day ago
Weekly Times Now, 1 week ago, 4 hours ago, 1 day ago
U.S. Food and Drug Administration, 1 week ago
EMax Health

FDA warns gluten-free ingredient lupin could cause allergic reaction

The increasing popularity of lupin as a food additive in gluten-free products is causing concern among some in the industry because of its potential to cause allergic reactions that many US consumers may not realize. According to FDA, which has ...
 Food Engineering10 hours ago Gluten-free food alert for people with peanut allergies: Celiac disease warning  EMax Health1 day ago Gluten-free doesn't necessarily mean problem-free  Consumer Affairs1 week ago Debt-free Lupin is ready for big acquisition: Vinita Gupta, CEO  Economic Times3 weeks ago
Business Standard

Pharma shares on a roll on strong growth prospects

Sun Pharma, Ranbaxy, Lupin and Glenmark Pharma gained more than 40% in past three months. Deepak Korgaonkar | Mumbai August 26, 2014 Last Updated at 11:21 IST Shares of pharmaceutical companies continued their upward march with most of the frontline stocks ...
 Business Standard1 day ago Bankex, Auto, Pharma, IT index hit new highs  Business Standard3 days ago Pharma shares on a roll; BSE Healthcare index up 3%  Business Standard1 week ago Pharma shares in demand; Healthcare index hits new high  Business Standard1 month ago

Risks to market remain global, not local: Credit Suisse

N Also read: See Nifty support at 7840; like Infy, Lupin: Growth Avenues According to him, index EPS growth could pick up to 11-12 percent from 7-8 percent, and a 30 percent return for the index over two years is quite likely even if the ...
 Moneycontrol.com2 days ago See Nifty support at 7840; like Infy, Lupin: Growth Avenues  Money Control2 days ago
U.S. Food and Drug Administration

Lupins filling in Western Australia

Lupins flowering in
 ABC Online2 days ago Legume Lupin on FDA Radar as Risky Allergen  General Medicine eJournal1 week ago FDA warns of allergic reactions to lupin  Orthopedics Today1 week ago Allergies to a Legume Called Lupin: What You Need to Know  U.S. Food and Drug Administration1 week ago

Is Lupin lining up a bid for Wockhardt?

Lupin's managing director says there are some synergies and a lot of duplication between the two companies
 DNA2 days ago Lupin to set up two new R&D centres in US  Business Standard1 month ago Lupin to set up two new RD centres in US  The Financial Chronicle1 month ago IT sector beats financial firms in salary payouts  Rediff.com2 months ago
Business Standard

Lupin studied Wockhardt for possible acquisition

Wockhardt currently has a market value of about Rs 7,890 cr Bloomberg August 26, 2014 Last Updated at 00:13 IST Lupin Ltd, the second-largest drugmaker by market value in India, studied Wockhardt Ltd as a potential acquisition candidate, although it hasn't ...
 Business Standard2 days ago Lupin took hard look at troubled Wockhardt for possible bid  FiercePharmaManufacturing2 days ago

Moody's upbeat on India pharma sector; Lupin, Ranbaxy, Cipla hit fresh 52-week high

NEW DELHI: Rating agency, Moody's is of the view that consolidations in the Indian pharma sector is likely to continue, particularly among generic drug players and will drive shareholder value going forward. India-based pharmaceutical companies ...
 Economic Times3 days ago

Sun shines in pharma space; M-cap greater than DRL, Lupin, Cipla & Ranbaxy combined

The market capitalisation of Sun Pharmaceuticals exceeded that of Dr Reddy's, Lupin, Cipal and Ranbaxy Laboratories combined on Wednesday, August 20. NEW DELHI: Sun Pharma, which has rallied nearly 50 per cent so far in the year 2014, has beaten its peers in ...
 Economic Times6 days ago Sun Pharma's M-cap > DRL + Lupin + Cipla + Ranbaxy  Economic Times6 days ago

Checkout: Religare Capital's top pharma bets

Arvind Bothra picks Aurobindo Pharma as his favourite bet among midcaps and Sun Pharma and Lupin among large caps.
 Money Control6 days ago Lupin CFO Ramesh Swaminathan on growth strategy and new geographies it plans to enter  VC Circle1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less